Aethlon Medical Inc 2026年季度报告

(Mark One) Aethlon Medical, Inc. Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of February 11, 2026, the registrant had outstanding 1,315,110 shares of common stock, $0.001 par value. PART I.FINANCIAL INFORMATION ITEM 1.FINANCIAL STATEMENTSCONDENSED CONSOLIDATED BALANCE SHEETS AT DECEMBER 31, 2025 (UNAUDITED) ANDMARCH 31, 2025 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHSENDED DECEMBER 31, 2025 AND 2024 (UNAUDITED)5 CAUTIONARY NOTICE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains “forward-looking statements” within the meaning of Section 27Aof the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or We may, in some cases, use words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,”“predict,” “project,” “should,” “will,” “would” or the negative of these terms, and similar expressions that convey uncertainty of futureevents or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historicalfacts may be deemed to be forward-looking statements and are based upon our current expectations, beliefs, estimates and projections,and various assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Such statements, include,but are not limited to, statements contained in this Quarterly Report relating to our business, business strategy, products and serviceswe may offer in the future, the timing and results of future clinical trials, and capital outlook, successful completion of our clinicaltrials, our ability to raise additional capital, our ability to maintain our Nasdaq listing, U.S. Food and Drug Administration, or FDA,approval of our products candidates, our ability to comply with changing government regulations, patent protection of our proprietarytechnology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factorsdetailed herein and in other of our filings with the Securities and Exchange Commission, or the SEC. Forward-looking statements arebased on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forwardlooking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict allof them, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, maycause actual results to differ materially from those contained in any forward-looking statements we may make. Given theseuncertainties, you should not place undue reliance on these forward-looking statements. We cannot guarantee future results, levels of The accompanying notes are an integral part of these condensed consolidated financial statements. AETHLON MEDICAL, INC. AND SUBSIDIARYNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)December 31, 2025 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION Aethlon Medical, Inc., or Aethlon, the Company, we or us, is a medical therapeutic company focused on developing theHemopurifier® (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections,and organ transplantation and other areas of significant unmet needs. In human studies (168 sessions with 42 patients), theHemopurifier was used safely and demonstrated the potential to remove enveloped viruses. In pre-clinical studies, the Hemopurifierhas exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing itsproprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immun